Feedback
Settings

Settings

Goto Application

37,609 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 3,761
1.WO/2026/101236PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
 Appl.No PCT/KR2025/018079 Applicant UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY Inventor BAE, Hyunsu
The present invention relates to a peptide, an antibody or an immunologically active fragment thereof, each specifically binding to CCR8, and a use thereof. It has been identified that CCR8-binding peptides newly discovered in the present invention bind to the TM sub-pocket of CCR8 in a pattern similar to that of CCL1, and actually specifically bind to cells having CCR8 expressed in the cell membrane thereof, and thus the proteins can be used as target materials for drug design targeting Tregs in which CCR8 is expressed and, when used, cytotoxic drugs can be specifically delivered to a tumor microenvironment or cancer cells without affecting other effector T cells or peripheral Tregs, and thus side effects of a conventional cancer immunotherapy agent can be reduced.
2.WO/2026/101356METHOD FOR ACTIVATING BRAIN REGULATORY T CELLS FOR AMELIORATING OR TREATING AUTISM
WO - 15.05.2026
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
 Appl.No PCT/KR2025/018471 Applicant UIF (UNIVERSITY INDUSTRY FOUNDATION), YONSEI UNIVERSITY Inventor KWON, Ho Keun
The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.
3.WO/2026/101896NOVEL PROGNOSTIC BIOMARKERS IN PATIENTS WITH CANCER
WO - 15.05.2026
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/US2025/053969 Applicant COMPASS THERAPEUTICS LLC Inventor SACHSENMEIER, Kris
The present disclosure relates to methods and systems for predicting a subject's responsiveness to treatment or therapy. Specifically, the methods and systems provided herein may predict whether a subject suffering from disease or cancer may respond to immune therapy, including treatment with an immune checkpoint inhibitor such as agonist anti-CD137 antibodies, PD-1 antagonists, anti-CTL4 antibodies, or any combination thereof.
4.WO/2026/099871MULTIPLEX RAPID DIAGNOSTIC KIT FOR SIMULTANEOUS DETECTION OF VECTOR-BORNE DISEASES
WO - 15.05.2026
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No PCT/IN2025/050008 Applicant TUNGA, Rashbehari Inventor TUNGA, Rashbehari
The present invention relates to a multiplex and simultaneous antigen detection kit (200) for the rapid diagnosis of Dengue, Chikungunya, and two forms of Malaria (Plasmodium vivax and Plasmodium falciparum) from whole blood samples. Utilizing vertical flow technology, the kit allows the detection of multiple antigens concurrently, offering faster results with enhanced sensitivity and specificity compared to traditional lateral flow assays. The diagnostic device employs metal nanoparticles and gold conjugates to detect the specific antigens, facilitating co-infection detection without the need for serum or plasma separation.
5.WO/2026/099598A DIAGNOSTIC METHOD
WO - 15.05.2026
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/GB2025/052448 Applicant UNIVERSITY OF LEICESTER Inventor BRINDLE, Nicholas
The invention relates to diagnostic methods, and particularly, although not exclusively, to the use of oligomeric protein traps in sample diagnostics. The invention extends to the use of oligomeric protein traps as binding agents, for example in methods for enriching samples of low-concentration proteins and/or genetic material, and methods for detecting the same in samples. The invention also encompasses high-affinity protein traps and their application in environmental monitoring, diagnosis and therapy.
6.WO/2026/102355MULTI-EPITOPE ANTIGENIC POLYPEPTIDES DERIVED FROM ACINETOBACTER BAUMANNII AND IMMUNOTHERAPEUTIC USES THEREOF
WO - 15.05.2026
Int.Class C07K 16/1217
Appl.No PCT/US2025/054703 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor ARULANANDAM, Bernard, P.
A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.
7.WO/2026/099711METHOD TO DEFINE A DOSE-RESPONSE
WO - 15.05.2026
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/IB2025/061176 Applicant CELLPLY S.R.L. Inventor BOCCHI, Massimo
method for defining a D/R dose- response curve, measured on target cells in a microfluidic system. The method is particularly advantageous when the therapeutic agent is an effector cell, or the therapeutic effect is mediated by an effector cell, as is the case with immunotherapies.
8.WO/2026/099408NOVEL DIAGNOSTIC AND THERAPEUTIC APPROACHES FOR OROPOUCHE VIRUS INFECTION
WO - 15.05.2026
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/EP2025/082237 Applicant INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE Inventor AMARA, Ali
The present invention reveals MESD as a critical host dependency factor for Oropouche virus (OROV) infection. Initial identification was achieved through a CRISPR-Cas9 loss-of-function screen, which highlighted MESD amongst other potential factors. The ensuing research demonstrated that MESD knockout in HEK293T cells resulted in a significant reduction in OROV infection rates. Complementing MESDKO cells with FLAG-MESD re-established susceptibility, thus confirming MESD's essential role in the infection process. Interestingly, MESD specifically facilitates OROV infection without enhancing the infectivity of other viruses such as LACV, TOSCV, and WNV. The specificity of MESD for OROV was further validated by its interaction with OROV envelope glycoproteins, as shown through immunoprecipitation assays. These findings suggest that targeting MESD could be a novel and effective approach for diagnosing and treating OROV infections, potentially paving the way for innovative therapeutic strategies against this virus.
9.20260126440METHODS FOR MEASURING LYMPHOCYTE ACTIVITY
US - 07.05.2026
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No 19375588 Applicant Kite Pharma, Inc. Inventor Chad M. Williams

Provided herein are methods for measuring antigen recognition response by lymphocytes upon exposure to a target antigen. Methods are disclosed for functionalizing red blood cells with antigens recognized by lymphocytes. By contacting antigen functionalized red blood cells with lymphocytes having specificity for the antigen, lymphocyte recognition response can be measured. The recognition response can be in the form of cytokine release by the lymphocytes and/or the expression of activation and/or differentiation markers on the surface of the lymphocytes.

10.WO/2026/093172A METHOD OF QUANTIFYING AND DIFFERENTIATING SEROLOGICAL RESPONSES TO MPOX INFECTION AND VACCINATION
WO - 07.05.2026
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/EP2025/080884 Applicant UNIVERSITY COLLEGE DUBLIN Inventor MALLON, Patrick
An immunoassay is described that enables a precise evaluation of immune responses in individuals exposed to Mpox or vaccinated with MVA, with high sensitivity and specificity. The serological assay targets three Orthopoxvirus antigens, MPXV-B6R, MPXV-A27L, and VACV-B5R, which are sufficient to quantify antibody responses to both MVA-vaccination (VACV-B5R) and, separately, infection (MPXV-B6R). The three antigen titres can be combined in a simple function [sum of ((MPXV-B6R)/VACV-B5R) and (MPXV-A27L)] to provide a numerical test score that can be compared with a reference (threshold) value to differentiate between post infection and post vaccination immune responses.
# -